Close Menu

NEW YORK – Luminex reported after the close of the market on Monday that its 2019 third quarter revenues were up 9 percent year over year.

For the quarter ended Sept. 30, the molecular diagnostics company reported revenues of $78.7 million compared to $72.4 million in the year-ago quarter, and missed the average Wall Street estimate for revenues of $81.8 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.